Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $769

Benzinga Newsdesk www.benzinga.com Negative 54.2%

Neg 54.2% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $778 to $769.